Clinical trials: ST-Segment Elevation Myocardial Infarction (STEMI)
- Condition ST-Segment Elevation Myocardial Infarction (STEMI)
- Funder type Industry (pharma, biotech, devices)
ST Elevation Myocardial Infarction
Efficacy, Safety and Tolerability of ATH3G10 in Patients With ST-elevation Myocardial Infarction
Patients with ST-segment elevation myocardial infarction (STEMI) that have suffered a major anterior wall infarction or where coronary blood flow is less than normal in spite of successful percutaneous coronary intervention (PCI)…
- Trial name
- NCT03991143
- Testing
- ATH3G10
- Where
- Sweden
- Volunteers
- 82 people
- Sponsor
- Athera Biotechnologies AB
ST Elevation Myocardial Infarction
Dutogliptin in Co-administration With Filgrastim in Early Recovery Post-myocardial Infarction
The goal of this phase 3, randomized, double-blind, placebo-controlled clinical trial is to explore the safety and efficacy of dutogliptin administered subcutaneously (SC) in co-administration with filgrastim in adult patients…
- Trial name
- HEAL-MI (NCT05881382)
- Testing
- Dutogliptin + Filgrastim
- Volunteers
- 4,100 people
- Sponsor
- Recardio, Inc.
Acute Myocardial Infarction, ST Elevation Myocardial Infarction
A Study of the Safety and Efficacy of Injectable Thymosin Beta 4 for Treating Acute Myocardial Infarction
The objective of this study is to evaluate the safety and tolerability of two active doses of RGN-352 (thymosin beta 4, Tβ4, Injectable Solution) in patients with acute myocardial infarction receiving percutaneous coronary…
- Conditions
- Acute Myocardial Infarction, ST Elevation Myocardial Infarction, STEMI
- Trial name
- NCT01311518
- Testing
- Drug: Injectable Thymosin beta 4
- Sponsor
- RegeneRx Biopharmaceuticals, Inc.
Myocardial Infarction
Feasibility of High Frequency QRS Analysis in Patients With Acute Myocardial Infarction
The primary objective of this study is to characterize the morphological patterns of high frequency QRS components (HFQRS) in patients with acute myocardial infarction (AMI), including STEMI and NSTEMI, compared to patients…
- Trial name
- NCT01150825
- Where
- Israel
- Volunteers
- 50 people
- Sponsor
- BSP Biological Signal Processing Ltd.
STEMI, Dyslipidemias
The Safety and Long-Term Clinical Benefit of PCSK9i in STEMI Patients
Patients with acute coronary syndromes (ACS) have an increased risk of recurrent ischemic events, particularly during the first year following the index event, which is mainly due to unattended risk factors and/ or poor…
- Trial name
- NCT05579418
- Testing
- Evolocumab
- Volunteers
- 350 people
- Sponsor
- Hamad Medical Corporation
Acute Coronary Syndrome
European Ambulance Acute Coronary Syndrome (ACS) Angiography Trial
To show that the early administration of bivalirudin improves 30 day outcomes when compared to the current standard of care in participants with ST segment elevation acute coronary syndrome (STE-ACS), intended for a primary…
- Trial name
- EUROMAX (NCT01087723)
- Testing
- Bivalirudin, Heparin
- Where
- 145 sites in Austria, Czechia and 7 more
- Volunteers
- 2,198 people
- Sponsor
- The Medicines Company
Myocardial Infarction
MCC-135 as Adjunct Therapy to Primary Percutaneous Coronary Intervention in ST-Segment Elevation Acute Myocardial Infarction Patients
This study is a multicenter, randomized, double-blind, placebo-controlled clinical trial. The primary objectives of this study are to examine the safety, tolerability, and efficacy of intravenous MCC-135 in limiting final infarct…
- Trial name
- NCT00078013
- Testing
- MCC-135
- Where
- United States
- Volunteers
- 414 people
- Sponsor
- Tanabe Pharma Corporation
Coronary Artery Disease, Coronary Syndrome
Intracoronary Cryotherapy Effect on Stabilization of Vulnerable Plaque in Patients With (N)STEMI or Unstable Angina
The POLARSTAR study is an early safety and feasibility study to evaluate the performance and safety of the CryoTherapy System (CTS) for the treatment of coronary plaque lesions that are not obstructing blood flow but are at…
- Conditions
- Coronary Artery Disease, Coronary Syndrome, Cryotherapy Effect, Myocardial Infarction
- Trial name
- POLARSTAR (NCT05600088)
- Testing
- CryoTherapy System (CTS)
- Where
- 5 sites in Georgia, Lithuania
- Volunteers
- 24 people
- Sponsor
- Cryotherapeutics SA
Coronary Artery Disease, Myocardial Ischemia
BIOFLOW-III Sweden Satellite Registry
This registry is a clinical post-market evaluation of the Orsiro LESS in subjects requiring coronary revascularization with Drug Eluting Stents (DES).
- Trial name
- NCT01667003
- Where
- 8 sites in Sweden
- Volunteers
- 406 people
- Sponsor
- Biotronik ApS
Acute Myocardial Infarction, ST Elevation MI
Nitric Oxide in Myocardial Infarction Size
The purpose of this study is to assess whether or not inhaled nitric oxide can decrease myocardial infarction (MI) size at 48-72 hours in patients presenting with an ST segment elevation MI (STEMI) who undergo successful…
- Conditions
- Acute Myocardial Infarction, ST Elevation MI, STEMI
- Trial name
- NOMI (NCT00568061)
- Testing
- Nitric Oxide
- Where
- 14 sites in United States, Belgium and 1 more
- Volunteers
- 29 people
- Sponsor
- Mallinckrodt
Myocardial Infarction
Single Bolus Recombinant Nonimmunogenic Staphylokinase Versus Single Bolus Tenecteplase (Metalyse) in STEMI
The aim of the study is to determine if single-bolus recombinant nonimmunogenic staphylokinase is effective and save thrombolytic agent in patients presenting ST-segment elevation myocardial infarction in comparison to…
- Trial name
- FRIDOM1 (NCT02301910)
- Testing
- Recombinant staphylokinase, Tenecteplase
- Where
- 17 sites in Russia
- Volunteers
- 382 people
- Sponsor
- Supergene, LLC
Acute ST Segment Elevation Myocardial Infarction
ABSORB STEMI: the TROFI II Study
This is a Prospective, randomized (1:1), active control, single-blind, non-inferiority, European multicenter clinical trial. The primary objective of this study is to assess the neointimal healing score (as evaluated by…
- Trial name
- NCT01986803
- Testing
- Percutaneous Coronary Intervention
- Where
- 8 sites in Denmark, Netherlands and 2 more
- Volunteers
- 191 people
- Sponsor
- ECRI bv
Acute Anterior Myocardial Infarction
The INFUSE - Anterior Myocardial Infarction (AMI) Study
This is a multicenter, open-label, controlled, single-blind, randomized study with up to 452 subjects enrolled in up to 50 US and European sites.
- Trial name
- NCT00976521
- Testing
- Abciximab local infusion, No local infusion, Thrombus aspiration
- Where
- 38 sites in United States, Austria and 4 more
- Volunteers
- 452 people
- Sponsor
- Atrium Medical Corporation
Coronary Stenosis, Acute Coronary Syndrome
Multiomics and Imaging-based Assessment of Vulnerable Coronary Plaques in Acute Coronary Syndromes
The aim of Multiplaque clinical study is to assess the vulnerability degree of the atheromatous plaques, before and after a myocardial infarction (MI), based on multiomics analysis, associated with invasive and non-invasive data.
- Conditions
- Coronary Stenosis, Acute Coronary Syndrome, Acute Myocardial Infarction, Atheromatous Plaques
- Trial name
- MultiPlaque (NCT03391908)
- Testing
- cardiac imaging tests
- Where
- Romania
- Volunteers
- 100 people
- Sponsor
- Cardio Med Medical Center
Acute Myocardial Infarction
Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI
The purpose of this study is to evaluate the efficacy and safety of LCZ696 titrated to a target dose of 200 mg twice daily, compared to ramipril titrated to a target dose of 5 mg twice daily.
- Trial name
- PARADISE-MI (NCT02924727)
- Testing
- LCZ696 (sacubitril/valsartan), Ramipril, Valsartan
- Where
- 486 sites in United States, Argentina and 39 more
- Volunteers
- 5,669 people
- Sponsor
- Novartis Pharmaceuticals
ST Elevation (STEMI) Myocardial Infarction of Anterior Wall
Primary Unloading and Delayed Reperfusion in ST-Elevation Myocardial Infarction: The STEMI-DTU Trial
The purpose of this research study is to evaluate whether using the the IMPELLA® CP System temporary circulatory assist device for 30 minutes prior to a catheterization procedure has the potential to reduce the damage to the…
- Trial name
- DTU-STEMI (NCT03947619)
- Testing
- Impella CP® placement prior to reperfusion with Primary PCI
- Where
- 63 sites in United States, Canada and 4 more
- Volunteers
- 527 people
- Sponsor
- Abiomed Inc.
Coronary Artery Disease, Myocardial Ischemia
BIOFLOW-III Israel Satellite Registry
BIOTRONIK - SaFety and Performance Registry for a diabetic patient population with the .bimus Eluting Orsiro Stent System Within daily clinical practice - III
- Conditions
- Coronary Artery Disease, Myocardial Ischemia, Diabetes Mellitus Type 1 or 2
- Trial name
- NCT01895712
- Where
- 6 sites in Israel
- Volunteers
- 120 people
- Sponsor
- BIOTRONIK Israel
Angina Pectoris, Unstable Angina
Pilot Study of Hemoglobin Based Oxygen Therapeutics in Elective Coronary Revascularization
The purpose of this study is to assess the safety and feasibility of a novel oxygen carrying solution, HBOC-201, in the setting of PCI for Acute Coronary Syndromes from randomization til hospital discharge.
- Conditions
- Angina Pectoris, Unstable Angina, Myocardial Infarction
- Trial name
- NCT00317512
- Testing
- Percutaneous Coronary Revascularization, Hemoglobin-Based Oxygen Carrier-201 (HBOC-201), Voluven
- Where
- 6 sites in Belgium, Germany and 1 more
- Volunteers
- 45 people
- Sponsor
- Biopure Corporation
STEMI
Efficacy and Safety on Prouk for STEMI Patients in China
The purpose of the study is to evaluate the efficacy and safety of rh-prouk as pharmacoinvasive therapy on those ST Elevated Myocardial Infarctions patients, it is designed as a multicenter, active controlled, single blinded…
- Trial name
- NCT02367976
- Testing
- rhprouk
- Where
- China
- Volunteers
- 450 people
- Sponsor
- Suzhou RxD Biopharmaceutical Co., Ltd
Myocardial Infarction
Efficacy and Safety of OPL-0301 Compared to Placebo in Adults With Post-Myocardial Infarction (MI)
Study OPL-0301-201 is intended to generate efficacy and safety data of OPL-0301 in participants with post-myocardial infarction (MI) left ventricular dysfunction (LVD)
- Trial name
- RESTORE (NCT05327855)
- Testing
- OPL-0301 Dose 1, OPL-0301 Dose 2
- Sponsor
- Valo Health, Inc.